此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

NVAMD Satellite Study

2018年8月28日 更新者:Johns Hopkins University

A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy

Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for near monthly administration of therapy coupled with the growing number of patients needing treatment has become a universal challenge in efficient delivery of care for retina physicians. While many retina practices have both increased the size of their staffs to accommodate the growing patient population and increased efficiency with the aid of digital photography, patient encounter times in clinic continue to increase, often spanning 2-4 hours. While maintaining the highest level of patient care, a streamlined alternative in the evaluation of patients with NVAMD to determine whether intravitreal therapy with an anti-VEGF agent is indicated at a particular office visit would be desirable.

This multi-satellite, prospective, randomized pilot study will compare standard-of-care, physician- based retinal evaluation, defined as retinal examination by a physician and standard imaging with optical coherence tomography (OCT) and optional fluorescein angiography (FA), versus physician-guided diagnostic evaluation, defined as standard imaging with OCT and optional FA without retinal examination by a physician in the management of NVAMD with anti-VEGF therapy. Outcomes for this study are aimed primarily at demonstrating that the physician-guided diagnostic approach to managing patients with NVAMD is not inferior to the physician-based retinal evaluation based on measures such as a change from baseline in visual acuity and in central subfield thickness (CSF) on OCT. Other outcomes to be assessed in this study are length of visit times, numbers of intravitreal injections of anti-VEGF agents administered, numbers of diagnostic tests performed to determine whether treatment should be given at each visit, and frequency of retinal examinations performed for each participating patient in each cohort. Perceptions of quality of vision and patient satisfaction will be captured by interviews with patients following each clinic visit; clinical impressions of physicians will be captured by a brief physician survey. Finally, the feasibility of recruiting patients, as measured by how many eligible patients are seen at each Wilmer satellite, how many patients agree to be randomized, how many patients follow-up, and the attrition rates at the 4 and 8-month outcome visits will be assessed.

研究概览

研究类型

介入性

注册 (实际的)

66

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Bel Air、Maryland、美国、21014
        • Wilmer Eye Institute
      • Bethesda、Maryland、美国、20814
        • Wilmer Eye Institute
      • Columbia、Maryland、美国、21044
        • Wilmer Eye Institute
      • Frederick、Maryland、美国、21702
        • Wilmer Eye Institute
      • Lutherville、Maryland、美国、21093
        • Wilmer Eye Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion criteria:

  • Established diagnosis of NVAMD in one or both eyes
  • Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
  • Need for more therapy on a near monthly basis is anticipated
  • Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
  • Must be physically able to cooperate with OCT and other diagnostic imaging procedures
  • Must be able to give informed consent and be able to complete telephone surveys

Exclusion criteria:

  • Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
  • History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
  • History of retinal surgery will not be enrolled.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
无干预:SOC Examination Based Cohort
Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
有源比较器:Physician-Guided Diagnostic
Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Change in visual acuity from baseline
大体时间:up to two years
up to two years
Change in OCT CSF from baseline
大体时间:up to two years
up to two years

次要结果测量

结果测量
大体时间
total encounter time for each arm
大体时间:up to two years
up to two years

其他结果措施

结果测量
大体时间
Number of intravitreal anti-VEGF injections administered
大体时间:up to two years
up to two years
number of diagnostic tests performed
大体时间:up to two years
up to two years
number of retinal examinations performed
大体时间:up to two years
up to two years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sharon Solomon, MD、Johns Hopkins University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年10月1日

初级完成 (实际的)

2016年10月30日

研究完成 (实际的)

2016年10月30日

研究注册日期

首次提交

2014年9月9日

首先提交符合 QC 标准的

2014年9月25日

首次发布 (估计)

2014年9月29日

研究记录更新

最后更新发布 (实际的)

2018年8月31日

上次提交的符合 QC 标准的更新

2018年8月28日

最后验证

2018年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • NA_00088759

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅